Cover Image

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial

The androgen receptor (AR) is discussed as a prognostic and/or predictive marker in breast cancer patients. AR mRNA expression was analysed by RT-qPCR in breast cancer patients treated in the neoadjuvant TECHNO (n  =  118, HER2-positive) and PREPARE trial (n  =  321, HER2-positive and -negative). In...

Full description

Saved in:
Bibliographic Details
Main Authors: Witzel, Isabell (Author) , Loibl, Sibylle (Author) , Wirtz, Ralph (Author) , Fasching, Peter A. (Author) , Denkert, Carsten (Author) , Weber, Karsten (Author) , Lück, Hans-Joachim (Author) , Huober, Jens (Author) , Karn, Thomas (Author) , Mackelenbergh, Marion von (Author) , Marmé, Frederik (Author) , Schem, Christian (Author) , Stickeler, Elmar (Author) , Untch, Michael (Author) , Müller, Volkmar (Author)
Format: Article (Journal)
Language:English
Published: 15 November 2019
In: British journal of cancer
Year: 2019, Volume: 121, Issue: 12, Pages: 1009-1015
ISSN:1532-1827
DOI:10.1038/s41416-019-0630-3
Online Access:Verlag, Volltext: https://doi.org/10.1038/s41416-019-0630-3
Verlag: https://www.nature.com/articles/s41416-019-0630-3
Get full text
Author Notes:Isabell Witzel, Sibylle Loibl, Ralph Wirtz, Peter A. Fasching, Carsten Denkert, Karsten Weber, Hans-Joachim Lück, Jens Huober, Thomas Karn, Marion von Mackelenbergh, Frederik Marmé, Christian Schem, Elmar Stickeler, Michael Untch, Volkmar Müller
Description
Summary:The androgen receptor (AR) is discussed as a prognostic and/or predictive marker in breast cancer patients. AR mRNA expression was analysed by RT-qPCR in breast cancer patients treated in the neoadjuvant TECHNO (n  =  118, HER2-positive) and PREPARE trial (n  =  321, HER2-positive and -negative). In addition, mRNA expression of the AR transcript variants 1 (AR1) and 2 (AR2) was measured. Regarding subtypes, high AR mRNA levels were frequent in HER2-positive (61.3%, 92/150) and luminal tumours (60.0%, 96/160) but almost absent in triple-negative tumours (4.3%, 3/69) (p < 0.0001). Overall, high AR mRNA levels were found to be associated with lower pathological complete remission (pCR) rates (OR 0.77 per unit, 95% CI 0.67-0.88, p  =  0.0002) but also with better prognosis in terms of longer disease-free survival (DFS) (HR 0.57, 95% CI 0.39-0.85, p  =  0.0054) and overall survival (OS) (HR 0.43, 95% CI, 0.26-0.71, p  =  0.0011). In the PREPARE trial, a survival difference for patients with high and low AR1 mRNA levels could only be seen in the standard chemotherapy arm but not in the dose-dense treatment arm (OS: HR 0.41; 95% CI 0.22-0.74 vs. HR 1.05; 95% CI 0.52-2.13; p  =  0.0459). We provide evidence that AR mRNA predicts response to chemotherapy in breast cancer patients.
Item Description:Gesehen am 03.03.2020
Physical Description:Online Resource
ISSN:1532-1827
DOI:10.1038/s41416-019-0630-3

Similar Items